Correlation of the MIC and Dose/MIC Ratio of Fluconazole to the Therapeutic Response of Patients with Mucosal Candidiasis and Candidemia

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2007-07-23

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/AAC.00296-07PMID 17646421PMCID PMC2043257
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fluconazole

  2012influential reference
• EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts: Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST)∗

  2008cited by this paper
• Statistical Analyses of Correlation between Fluconazole MICs for Candida spp. Assessed by Standard Methods Set Forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2)

  2006cited by this paper
• Impact of Antimicrobial Dosing Regimen on Evolution of Drug Resistance In Vivo: Fluconazole and Candida albicans

  2006cited by this paper
• Association of Fluconazole Area under the Concentration-Time Curve/MIC and Dose/MIC Ratios with Mortality in Nonneutropenic Patients with Candidemia

  2006cited by this paper
• Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing

  2006influential reference
• A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit.

  2005cited by this paper
• Fluconazole MIC and the Fluconazole Dose/MIC Ratio Correlate with Therapeutic Response among Patients with Candidemia

  2005cited by this paper
• Epidemiology and Predictors of Mortality in Cases of Candida Bloodstream Infection: Results from Population-Based Surveillance, Barcelona, Spain, from 2002 to 2003

  2005cited by this paper
• Clinical factors associated with fluconazole resistance and short-term survival in patients with Candida bloodstream infection

  2004cited by this paper
• Use of Monte Carlo Simulations To Select Therapeutic Doses and Provisional Breakpoints of BAL9141

  2004cited by this paper
• Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST).

  2003cited by this paper
• European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria.

  2003cited by this paper
• Method for the determination of minimum inhibitory concentration (MIC) by broth dilution of fermentative yeasts

  2003cited by this paper
• Comparative Evaluation of NCCLS M27-A and EUCAST Broth Microdilution Procedures for Antifungal Susceptibility Testing of Candida Species

  2002cited by this paper
• A Brief Introduction to Monte Carlo Simulation

  2001cited by this paper
• Use of Preclinical Data for Selection of a Phase II/III Dose for Evernimicin and Identification of a Preclinical MIC Breakpoint

  2001cited by this paper
• Population Pharmacokinetics and Use of Monte Carlo Simulation To Evaluate Currently Recommended Dosing Regimens of Ciprofloxacin in Adult Patients with Cystic Fibrosis

  2001cited by this paper
• Influence of Glucose Supplementation and Inoculum Size on Growth Kinetics and Antifungal Susceptibility Testing ofCandida spp

  2001cited by this paper
• Antifungal Susceptibility Testing: Practical Aspects and Current Challenges

  2001cited by this paper
• Use of Drug Effect Interaction Modeling with Monte Carlo Simulation To Examine the Impact of Dosing Interval on the Projected Antiviral Activity of the Combination of Abacavir and Amprenavir

  2000cited by this paper
• The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae.

  2000cited by this paper
• Clinical Correlates of Antifungal Macrodilution Susceptibility Test Results for Non-AIDS Patients with Severe CandidaInfections Treated with Fluconazole

  2000cited by this paper
• Characterization and Quantitation of the Pharmacodynamics of Fluconazole in a Neutropenic Murine Disseminated Candidiasis Infection Model

  1999cited by this paper
• Pharmacokinetic Studies of Fluconazole in Rabbits Characterizing Doses Which Achieve Peak Levels in Serum and Area under the Concentration-Time Curve Values Which Mimic Those of High-Dose Fluconazole in Humans

  1998influential reference
• Pharmacodynamics of Fluconazole in a Murine Model of Systemic Candidiasis

  1998cited by this paper
• Patterns of fluconazole susceptibility in isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis due to Candida albicans.

  1997cited by this paper
• Fluconazole. An update of its antimicrobial activity, pharmacokinetic properties, and therapeutic use in vaginal candidiasis.

  1995cited by this paper
• Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.

  1995cited by this paper
• Clinical Pharmacokinetics of Fluconazole

  1993influential reference
• Pharmacokinetics and tissue penetration of fluconazole in humans.

  1990influential reference
• National Committee for Clinical Laboratory Standards.

  1980cited by this paper

• Antifungal susceptibility testing and determination of local epidemiological cut-off values for Candida species isolated from women with vulvovaginal candidiasis

  2025cites this paper
• Studying the effect bio-based sensorns packaging based on magnetic fields extraction of phycocyanin on the shelf life of fish fillets infected with Staphylococcus aureus

  2025cites this paper
• A Pharmacokinetic Analysis of Intravenous Fluconazole in Adult Patients Undergoing Mechanical Circulatory Support Device Implantation.

  2025cites this paper
• Fluconazole step-down therapy versus echinocandins for the treatment of Candida glabrata invasive candidiasis with candidaemia.

  2025cites this paper
• Population pharmacokinetics of fluconazole for prevention or treatment of invasive candidiasis in Chinese young infants

  2024cites this paper
• Parametric and nonparametric population pharmacokinetic analysis of fluconazole in critically ill patients and dosing simulations for Candida infections

  2024cites this paper
• Candidemia in Adult Patients in the ICU: A Reappraisal of Susceptibility Testing and Antifungal Therapy

  2023cites this paper
• Pharmacokinetic and pharmacodynamic considerations for antifungal therapy optimisation in the treatment of intra-abdominal candidiasis

  2023cites this paper
• Therapeutic Drug Monitoring of Antifungal Agents in Critically Ill Patients: Is There a Need for Dose Optimisation?

  2022cites this paper
• Glimpsing the chemical composition and the potential of Myrtaceae plant extracts against the food spoilage fungus Thielaviopsis ethacetica

  2022cites this paper
• Clinical utility of antifungal susceptibility testing

  2022cites this paper
• Susceptibility Testing of Candida auris Isolates.

  2022cites this paper
• Total bodyweight and sex both drive pharmacokinetic variability of fluconazole in obese adults.

  2022cites this paper
• Pharmacokinetic/Pharmacodynamic Target Attainment of Different Antifungal Agents in De-escalation Treatment in Critically Ill Patients: a Step toward Dose Optimization Using Monte Carlo Simulation

  2022cites this paper
• Managing uncertainty in antifungal dosing: antibiograms, therapeutic drug monitoring and drug-drug interactions

  2021cites this paper
• Resistance to Antifungal Drugs.

  2021cites this paper
• Population Pharmacokinetic Modeling of Total and Free Ceftriaxone in Critically Ill Children and Young Adults and Monte Carlo Simulations Support Twice Daily Dosing for Target Attainment

  2021cites this paper
• Population Pharmacokinetic Analysis and Dosing Optimization of Prophylactic Fluconazole in Japanese Patients with Hematological Malignancy

  2021cites this paper
• Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021

  2021cites this paper
• Precision Therapy for Invasive Fungal Diseases

  2021cites this paper
• Model‐Informed Drug Development for Anti‐Infectives: State of the Art and Future

  2021cites this paper
• Current fluconazole treatment regimens result in under-dosing of critically ill adults during early therapy

  2021cites this paper
• Model-Optimized Fluconazole Dose Selection for Critically Ill Patients Improves Early Pharmacodynamic Target Attainment without the Need for Therapeutic Drug Monitoring

  2020cites this paper
• Review of the Current Management of Urinary Tract Infections due to Fluconazole-Resistant and Non-Albicans Candida Species

  2020cites this paper
• Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#

  2020cites this paper
• Antifungal susceptibility testing in Candida, Aspergillus and Cryptococcus infections: are the MICs Useful for clinicians?

  2020cites this paper
• Usefulness of Yeast Cell Counting and Lack of Clinical Correlation of the Antifungal Susceptibility Testing Results in Management of Aids-associated Cryptococcal Meningitis

  2020cites this paper
• Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections

  2020cites this paper
• From bench to bedside: Perspectives on the utility of pharmacokinetics/pharmacodynamics in predicting the efficacy of antifungals in invasive candidiasis

  2020cites this paper
• Real-Time Therapeutic Drug Monitoring (TDM)-Based Pharmacokinetic/Pharmacodynamic (PK/PD) Optimization of Complex Antimicrobial Therapy in a Critically Ill Morbidly Obese Patient. Grand Round/A Case Study.

  2020cites this paper
• Simulating moxalactam dosage for extended-spectrum β-lactamase-producing Enterobacteriaceae using blood antimicrobial surveillance network data

  2019cites this paper
• Antifungal Resistance Testing and Implications for Management

  2019cites this paper
• The association between fluconazole dose and MIC with mortality and persistence in candidemia

  2019cites this paper
• Usefulness of Antifungal Reference In Vitro Susceptibility Tests as a Guide in Therapeutic Management

  2019cites this paper
• Overview of antifungal dosing in invasive candidiasis.

  2018cites this paper
• Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with Candida albicans and non-albicans spp.

  2018cites this paper
• Survival in Patients with Candida glabrata Bloodstream Infection Is Associated with Fluconazole Dose

  2018cites this paper
• Are In Vitro Susceptibilities to Azole Antifungals Predictive of Clinical Outcome in the Treatment of Candidemia?

  2018cites this paper
• Candida Species Distribution and Antifungal Susceptibility Testing According to EUCAST and New vs. Old CLSI Clinical Breakpoints: a Six-Year Prospective Candidemia Survey from the Fungal Infection Network of Switzerland (FUNGINOS)

  2017cites this paper
• Fluconazole levels in serum and cerebrospinal fluid according to daily dosage in patients with cryptococcosis and other fungal infections

  2017cites this paper
• Genotypic identification of cychloheximide resistance yeasts isolated from clinical cases with superficial mycosis

  2017cites this paper
• Impact of fluconazole susceptibility on the outcome of patients with candidaemia: data from a population-based surveillance.

  2017cites this paper
• In Vitro Susceptibilty Test of Fluconazole to Candida spp in Patients with Oropharyngeal Candidiasis and HIV/AIDS with Vitek II

  2017cites this paper
• In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen

  2017cites this paper
• General Concepts of Pharmacodynamics for Anti-infective Agents

  2016cites this paper
• Enfermedades Infecciosas y Microbiología Clínica

  2016cites this paper
• Tratamiento de las infecciones fungicas en pacientes con neoplasias hematologicas Treatment of fungal infections in patients with hematologic neoplasia

  2016cites this paper
• Antibiotic Pharmacodynamics

  2016cites this paper
• Antifungal pharmacodynamics: Latin America's perspective

  2016cites this paper
• Practical Pharmacokinetics and Pharmacodynamics

  2016cites this paper
• Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study

  2015cites this paper
• Training should be the first step toward an antifungal stewardship program.

  2015cites this paper
• How much European prescribing physicians know about invasive fungal infections management?

  2015cites this paper
• In Vivo Microdialysis To Determine Subcutaneous Interstitial Fluid Penetration and Pharmacokinetics of Fluconazole in Intensive Care Unit Patients with Sepsis

  2015cites this paper
• Antifungal activity of Uncaria tomentosa (Willd.) D.C. against resistant non-albicans Candida isolates

  2015cites this paper
• [Not Available].

  2015cites this paper
• Candida glabrata – unique features and challenges in the clinical management of invasive infections

  2015cites this paper
• Antifungal pharmacokinetics and pharmacodynamics.

  2015influential citation
• Oropharyngeal Candidiasis in Palliative Care Patients in Denmark

  2015cites this paper
• Differential association of fluconazole dose and dose/MIC ratio with mortality in patients with Candida albicans and non-albicans bloodstream infection.

  2015cites this paper
• Demonstration of Therapeutic Equivalence of Fluconazole Generic Products in the Neutropenic Mouse Model of Disseminated Candidiasis

  2015cites this paper
• Impact of New Antifungal Breakpoints on Antifungal Resistance in Candida Species

  2014cites this paper
• Antifungal drug discovery: the process and outcomes.

  2014cites this paper
• Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Sw

  2014cites this paper
• Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.

  2014cites this paper
• [Clinical indications for therapeutic drug monitoring of antifungal agents. In the way for optimizing the treatment of fungal infection].

  2014cites this paper
• Evaluation of antifungal use in a tertiary care institution: antifungal stewardship urgently needed.

  2014cites this paper
• Support for the EUCASTand revised CLSI fluconazole clinical breakpoints by Sensititre w YeastOne w for Candida albicans : a prospective observational cohort study

  2014cites this paper
• Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology

  2014cites this paper
• Support for the EUCAST and revised CLSI fluconazole clinical breakpoints by Sensititre® YeastOne® for Candida albicans: a prospective observational cohort study.

  2014cites this paper
• Antifungal Pharmacokinetics and Pharmacodynamics Subject Collection Human Fungal Pathogens Pneumocystis

  2014influential citation
• Applied Antifungal Pharmacometrics: Fluconazole and Echinocandins in the Treatment of Candidemia and Invasive Candidiasis

  2014cites this paper
• Setting Clinical MIC Breakpoints from a PK/PD Point of View: It Is the Dose That Matters

  2014cites this paper
• Fluconazole Pharmacokinetics in a Morbidly Obese, Critically Ill Patient Receiving Continuous Venovenous Hemofiltration

  2014cites this paper
• CORRELATION OF MINIMUM INHIBITORY CONCENTRATION OF CIPROFLOXACIN TO THE THERAPEUTIC RESPONSE OF PATIENT WITH URINARY TRACT INFECTION CAUSED BY ESCHERICHIA COLI

  2014cites this paper
• The Evolving Role of Antifungal Susceptibility Testing

  2013cites this paper
• Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options.

  2013cites this paper
• Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp.

  2013cites this paper
• Comparison between the EUCAST Procedure and the Etest for Determination of the Susceptibility of Candida Species Isolates to Micafungin

  2013cites this paper
• Estudios de sensibilidad en levaduras. Actualización y novedades

  2013cites this paper
• 21. Antimicrobial Resistance

  2013cites this paper
• Isavuconazole Pharmacodynamic Target Determination for Candida Species in an In Vivo Murine Disseminated Candidiasis Model

  2013cites this paper
• [Antifungal treatment options in the critically ill patient].

  2012cites this paper
• Caracterização e avaliação do perfil de suscetibilidade a antifúngicos dos agentes de candidemia em hospital público de referência da Baixada Santista, Brasil

  2012cites this paper
• Pulmonary Aspergillosis Model of Invasive In Vivo fumigatus in an Mutant Isolates of Aspergillus Cyp 51 Determination against Wild-Type and Posaconazole Pharmacodynamic Target

  2012cites this paper
• Optimizing Echinocandin Dosing and Susceptibility Breakpoint Determination via In Vivo Pharmacodynamic Evaluation against Candida glabrata with and without fks Mutations

  2012cites this paper
• Opciones terapéuticas para el tratamiento antifúngico en el paciente crítico

  2012cites this paper
• Antifungals: Drug Class, Mechanisms of Action, Pharmacokinetics/Pharmacodynamics, Drug-Drug Interactions, Toxicity, and Clinical Use

  2012cites this paper
• Utility of Antifungal Susceptibility Testing and Clinical Correlations

  2012cites this paper
• Interactions of Yeasts, Moulds, and Antifungal Agents

  2012cites this paper
• The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach.

  2012cites this paper
• Ten-Year Study of Species Distribution and Antifungal Susceptibilities of Candida Bloodstream Isolates at a Brazilian Tertiary Hospital

  2012cites this paper
• Reclassification of the Candida haemulonii Complex as Candida haemulonii (C. haemulonii Group I), C. duobushaemulonii sp. nov. (C. haemulonii Group II), and C. haemulonii var. vulnera var. nov.: Three Multiresistant Human Pathogenic Yeasts

  2012cites this paper
• Reclassification of the Candida haemulonii complex; C. 1 duobushaemulonii sp. nov. ( C. haemulonii group II) and C. 2 haemulonii var . vulnera var. nov.: Two multiresistant human 3 pathogenic yeasts. 4

  2012cites this paper
• Posaconazole Pharmacodynamic Target Determination against Wild-Type and Cyp51 Mutant Isolates of Aspergillus fumigatus in an In Vivo Model of Invasive Pulmonary Aspergillosis

  2012cites this paper
• Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment.

  2012cites this paper
• Эмпирическая терапия инвазивного кандидоза в отделениях реанимации и интенсивной терапии: современное состояние проблемы

  2011cites this paper
• Fungal sepsis: optimizing antifungal therapy in the critical care setting.

  2011cites this paper
• Susceptibility Test Methods: Yeasts and Filamentous Fungi*

  2011cites this paper
• Can We Achieve Clinical Breakpoints for the Triazoles in Aspergillosis?

  2011cites this paper